Table 1 Baseline characteristics of participants with all 190 TAK patients
Normal immunoglobulin (N = 147) | Elevated immunoglobulin (N = 43) | P-value | |
|---|---|---|---|
Demographic data | |||
Age, years | 38.6 ± 13.0 | 37.3 ± 10.6 | 0.549 |
Female, n (%) | 131 (89.1%) | 40 (93.0%) | 0.452 |
BMI, kg/m2 | 22.4 ± 3.1 | 22.0 ± 5.1 | 0.526 |
Duration of TAK, months | 60.0 (12.0–156.0) | 60.0 (12.0–120.0) | 0.290 |
Clinical symptoms | |||
Fever, n (%) | 20 (13.6%) | 5 (11.6%) | 0.736 |
Fatigue, n (%) | 63 (42.9%) | 20 (46.5%) | 0.671 |
Claudication, n (%) | 32 (21.8%) | 3 (7.0%) | 0.028 |
Blood pressure asymmetry in both upper limbs, n (%) | 56 (38.1%) | 16 (37.2%) | 0.916 |
Neck pain, n (%) | 21 (14.3%) | 3 (7.0%) | 0.204 |
Chest distress, n (%) | 39 (26.5%) | 13 (30.2%) | 0.632 |
Chest pain, n (%) | 31 (21.1%) | 9 (20.9%) | 0.982 |
Dizzy, n (%) | 73 (49.7%) | 17 (39.5%) | 0.242 |
Headache, n (%) | 32 (21.8%) | 7 (16.3%) | 0.433 |
Laboratory tests | |||
WBC, × 109/L | 7.4 ± 3.0 | 7.7 ± 2.3 | 0.544 |
ESR, mm/h | 14.0 (7.0–24.0) | 34.0 (18.0–67.0) | < 0.001 |
CRP, mg/L | 2.4 (0.6–8.6) | 12.5 (2.2–28.4) | < 0.001 |
C3, g/L | 1.1 ± 0.3 | 1.3 ± 0.2 | 0.004 |
C4, g/L | 0.2 (0.2–0.3) | 0.2 (0.2–0.3) | 0.408 |
B lymphocyte | 212.0 (151.0–357.0) | 259.0 (182.0–319.0) | 0.332 |
B lymphocyte, % | 13.4 ± 6.2 | 13.8 ± 5.2 | 0.739 |
Creatinine, µmol/L | 54.0 (47.0–64.5) | 56.2 (48.3–64.8) | 0.432 |
Aspartate aminotransferase, U/L | 17.0 (13.5–21.0) | 16.0 (12.2–19.7) | 0.103 |
Imaging type | |||
I, n (%) | 18, 12.24% | 11, 25.59% | 0.032 |
IIa, n (%) | 9, 6.12% | 1, 2.33% | 0.553 |
IIb, n (%) | 18, 12.24% | 8, 18.60% | 0.286 |
III, n (%) | 7, 4.76% | 2, 4.65% | 1.000 |
IV, n (%) | 5, 3.40% | 1, 2.33% | 1.000 |
V, n (%) | 90, 61.22% | 20, 46.51% | 0.086 |
Disease activity | |||
NIH score | 2.0 (2.0–3.0) | 3.0 (2.0–3.0) | 0.001 |
ITAS-A score | 7.0 (3.0–10.0) | 9.0 (6.0–12.0) | 0.006 |
ITAS2010 score | 6.0 (3.0–9.0) | 7.0 (3.5–9.0) | 0.267 |